Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk to bring weight-loss drug Wegovy to its customers.

Novo Nordisk (NVO) (OTCPK:NONOF) on Thursday announced a new initiative to promote its blockbuster weight loss therapy Wegovy for new self-paying patients as a grace period available for makers of cheaper versions of the drug ends.

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of its popular weight-loss drug and expand access to cash-paying patients.